Chimerix Inc. (NASDAQ:CMRX) shares were up 3.1% on Tuesday . The company traded as high as $4.68 and last traded at $4.64, with a volume of 116,372 shares changing hands. The stock had previously closed at $4.50.

A number of research analysts have recently weighed in on CMRX shares. Piper Jaffray Cos. set a $12.00 price objective on Chimerix and gave the company a “buy” rating in a research report on Thursday, August 18th. Zacks Investment Research upgraded Chimerix from a “hold” rating to a “buy” rating and set a $4.75 price objective for the company in a research report on Wednesday, August 10th. JPMorgan Chase & Co. restated a “hold” rating and set a $7.00 price objective on shares of Chimerix in a research report on Tuesday, August 9th. Finally, FBR & Co cut their price objective on Chimerix from $9.00 to $8.00 and set a “mkt perform” rating for the company in a research report on Tuesday, August 9th. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $15.72.

The firm’s 50 day moving average is $4.28 and its 200-day moving average is $4.81. The company’s market capitalization is $222.29 million.

Chimerix (NASDAQ:CMRX) last announced its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.51) by $0.12. The business had revenue of $1.80 million for the quarter, compared to analysts’ expectations of $1.98 million. On average, analysts expect that Chimerix Inc. will post ($1.78) EPS for the current fiscal year.

In other news, CEO M Michelle Berrey purchased 13,188 shares of the company’s stock in a transaction dated Friday, June 24th. The stock was acquired at an average price of $3.69 per share, with a total value of $48,663.72. Following the purchase, the chief executive officer now directly owns 258,821 shares in the company, valued at approximately $955,049.49. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, Director Ernest Mario purchased 50,000 shares of the company’s stock in a transaction dated Friday, June 24th. The stock was purchased at an average cost of $3.70 per share, with a total value of $185,000.00. Following the purchase, the director now owns 381,440 shares in the company, valued at $1,411,328. The disclosure for this purchase can be found here.

A hedge fund recently raised its stake in Chimerix stock. Jennison Associates LLC boosted its stake in shares of Chimerix Inc. (NASDAQ:CMRX) by 67.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,273,779 shares of the biopharmaceutical company’s stock after buying an additional 515,029 shares during the period. Jennison Associates LLC owned approximately 2.76% of Chimerix worth $11,400,000 as of its most recent filing with the SEC.

Chimerix, Inc (Chimerix) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing oral antivirals. The Company, based on its lipid conjugate technology, has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.